← All trials
NCT06890598
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 27, 2025
- Primary completion
- May 31, 2029
- Completion date
- Feb 29, 2032
- First posted
- Mar 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 700
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- AstraZenecaCollaborator
- Eli LillyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.